Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders

Libzon, Stephanie; Schleider, Lihi Bar-Lev; Saban, Naama; Levit, L; Tamari, Yulia; Linder, Ilan; Lerman‐Sagie, Tally; Blumkin, Lubov

doi:10.1177/0883073818773028

Cited by 55 publications

(42 citation statements)

References 27 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 Similar, modest improvements in pain were found in a small, non-controlled study that examined CBD and THC in 25 patients aged 1-17 years with complex motor disorders. 35 Two formulations of Avidekel whole plant CBDenriched 5% oil extract were used: CBD-to-THC ratio 6:1 and CBD-to-THC ratio 20:1. 35 After five months, participants reported a 1.41-point reduction in pain on a 10-point scale (p = 0.02).…”

Section: Efficacy Of Medical Cannabis In Pain Management Among Childrmentioning

confidence: 99%

<p>Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions</p>

Woo¹,

Reekum²,

Rosic³

et al. 2020

AHMT

View full text Add to dashboard Cite

We provide up-to-date perspectives on the benefits and risks of medical cannabis for pain management in children and youth. To date, only two studies (a case report and a small observational study) have examined the effects of medical cannabis on pain in children and youth. No controlled trial has commented on long-term safety of medical cannabis. Findings from the recreational cannabis literature reveal significant potential short-and long-term risks of regular cannabis use, including impaired driving, depression, suicidality, psychosis, and tolerance. Despite this, many children and youth are selfmedicating with cannabis, and perceive regular cannabis use to be safe. There is a need for better education and counselling of patients regarding the benefits and risks of medical cannabis use.

show abstract

Section: Efficacy Of Medical Cannabis In Pain Management Among Childrmentioning

confidence: 99%

<p>Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions</p>

Woo¹,

Reekum²,

Rosic³

et al. 2020

AHMT

View full text Add to dashboard Cite

show abstract

“…Five reports describe therapeutic cannabinoid use in 117 children and young adults (age range 3-27y). [47][48][49][50][51] These included one case report, 49 two case series, 47,50 and two smaller clinical trials, 48,51 one of which was described only in a conference abstract. 51 Causes of spasticity were heterogeneous, with cerebral palsy the largest group (Table I).…”

Section: Paediatric Studiesmentioning

confidence: 99%

“…In their pilot study, Libzon et al 48 compared two dose regimens of cannabinoid-enriched 5 per cent oil (THC ratios 6:1 and 20:1) in children with complex motor disorders (dystonia and spasticity). Improvements in spasticity, dystonia, and quality of life were described.…”

Section: Paediatric Studiesmentioning

confidence: 99%

Cannabinoids for the treatment of spasticity

Nielsen

Murnion

Campbell

et al. 2019

Develop Med Child Neuro

View full text Add to dashboard Cite

This review summarizes studies that examined the effectiveness of cannabinoids in treating spasticity, with a focus on understanding the relevance of the existing evidence to paediatric populations. MEDLINE, Embase, PsycINFO, and the Cochrane Library were searched to identify studies that examined the use of cannabinoids in spasticity. We identified 32 studies in adult and paediatric populations. Results were summarized by condition, with adult and paediatric studies considered separately. There is evidence from randomized controlled clinical trials that cannabinoids are more effective than placebo in reducing symptoms of spasticity in adults with multiple sclerosis. Most positive effects were based on patient‐rated rather than clinician‐rated measures, were modest in size, and should be considered in the context of the narrow therapeutic index of cannabinoids for spasticity and adverse effects. There were comparatively few, and no large studies, of spasticity in conditions other than multiple sclerosis. Few studies have been conducted in paediatric populations. Paediatric studies of spasticity provide low quality evidence and are inadequate to inform clinical practice. Cannabinoids have modest efficacy in reducing muscle spasticity in adults with multiple sclerosis. There is limited evidence of efficacy for cannabinoid use in other conditions, particularly in paediatric populations. Studies in paediatric populations have been of low quality and are insufficient to inform clinical practice.

show abstract

“…Two trials on spasticity in paediatrics patients suffering from cerebral palsy are in final stages, the first is a double blind, placebo control trial assessing safety and efficacy of Sativex® in 72 patients (NCT01898520, GW Research Ltd.), and the second is a randomized controlled trial comparing two cannabis oil formulations (5% CBD and 0.2% THC) and (5% CBD and 0.8% THC) provided by Tikun Olam Ltd in 40 patients (NCT02470325). In an intermediate analysis on 25 patients, adverse effects were rare and included worsening of seizures in 2 patients, behavioral changes in 2 and somnolence in 1 . A large double blind, randomized, placebo‐controlled trial with crossover that is now recruiting, is assessing the safety, tolerability and efficacy of whole plant extract versus 99% CBD oil and placebo (provided by BOL pharma ltd) in 120 patients with autism spectrum disorder (NCT02956226).…”

Section: Paediatricsmentioning

confidence: 99%

Medical cannabis: aligning use to evidence‐based medicine approach

Schleider

Abuhasira

Novack

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

During the past decade we have been witnessing a rise in medical cannabis use, yet the evidence for the safety and efficacy of the various cannabinoid compounds is scarce. The State of Israel has always been at the forefront of clinical and translational research in support of Evidence Based Medicine. With respect to cannabis Israel has created a medical and regulatory environment that enables clinical studies with cannabis which may lead to improved Evidence Based use of these compounds. This opinion paper discusses selected studies into the safety and effects of cannabis derived products.

show abstract

Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders

Cited by 55 publications

References 27 publications

<p>Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions</p>

<p>Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions</p>

Cannabinoids for the treatment of spasticity

Medical cannabis: aligning use to evidence‐based medicine approach

Contact Info

Product

Resources

About